Clinical Trial Readiness for Rare Lung Diseases (RLDC)

Grant number: U54 HL188781-01

Principal Investigators

• Francis X. McCormack, MD
• Bruce C. Trapnell, MS, MD

Lead Institution: University of Cincinnati

Diseases Studied

• Diffuse cystic lung diseases
• Pulmonary alveolar proteinosis
• Genetic fibrotic interstitial lung diseases

Funding Statement

The Clinical Trial Readiness for Rare Lung Diseases (RLDC) is part of the Rare Diseases Clinical Research Network (RDCRN), which is funded by the National Institutes of Health (NIH) and led by the National Center for Advancing Translational Sciences (NCATS) through its Division of Rare Diseases Research Innovation (DRDRI). RLDC is funded under grant number HL188781 as a collaboration between NCATS, the National Heart, Lung, and Blood Institute (NHLBI), and the National Human Genome Research Institute (NHGRI). This website is hosted by the network’s Data Management and Coordinating Center at Cincinnati Children’s Hospital Medical Center, which is funded by NCATS and the National Institute of Neurological Disorders and Stroke (NINDS) under grant number TR002818.